drugset / Trial / NCT00969917
Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary objective of the study is to determine the safety profile and overall response rate of IPI 504 in patients with advanced dedifferentiated liposarcoma.
Timeline
- Start
- 2010-01
- Primary completion
- 2010-12
- Completion
- 2010-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | retaspimycin | Small molecule | 225 mg/m2 | — |